Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

Some patients with diffuse large B-cell lymphoma (DLBCL) present with a concurrent indolent lymphoma at diagnosis. Their outcomes in the rituximab era are not fully defined. Using a prospectively followed cohort of 1324 newly diagnosed DLBCL patients treated with immunochemotherapy, we defined the p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Wang, Yucai, Link, Brian K., Witzig, Thomas E., Maurer, Matthew J., Allmer, Cristine, King, Rebecca L., Feldman, Andrew L., Habermann, Thomas M., Ansell, Stephen M., Slager, Susan L., Cerhan, James R., Nowakowski, Grzegorz S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888139/
https://ncbi.nlm.nih.gov/pubmed/31350266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000858
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge